Deutsche Bank Appointed as Depositary Bank for the Level II American Depositary Receipt (ADR) Program of Morria

  Deutsche Bank Appointed as Depositary Bank for the Level II American
  Depositary Receipt (ADR) Program of Morria Biopharmaceuticals Plc

Business Wire

NEW YORK & LONDON -- December 07, 2012

Deutsche Bank today announced its appointment as depositary bank for the Level
II American Depositary Receipt (ADR) program of Morria Biopharmaceuticals Plc

Morria Biopharmaceuticals PLC is a biopharmaceutical emerging growth company
focused on the development of non-steroidal, synthetic anti-inflammatory
drugs. Morria has developed a class of synthetic drugs termed MFAIDs
(Multi-Functional Anti-Inflammatory Drugs) representing a new therapeutic
platform for the treatment of a wide range of inflammatory diseases such as
allergies and autoimmune diseases. Morria currently has two lead product
candidates in its clinical pipeline, both of which have completed
first-in-patient clinicalstudies. MRX-4, a nasal spray for treating allergic
rhinitis (hay fever), and MRX-6, a topical cream for treating contact
dermatitis (a common type of eczema). Morria’s business strategy is to expand
and build a biopharmaceutical business to gradually focus on a spectrum of
inflammatory diseases based on its current and upcoming first in class product
candidates, that will fill the current unmet need for safe and potent
alternatives to steroids.

Mark Cohen, Executive Chairman of Morria said “This ADR listing will allow for
broad and diversified investor exposure within the US with potentially greater
liquidity. It also provides us with a flexible mechanism for raising capital
in the future. We are pleased to be working with Deutsche Bank which has an
excellent track record in healthcare finance and strong relationships with
investors in both the U.S. and Europe.”

Akbar Poonawala, Head of Global Equity Services at Deutsche Bank said, “We are
delighted to be appointed as the depositary bank for Morria’s ADR program.
Deutsche Bank's range of customized ADR-related services will be utilized to
assist in enhancing its ADR program visibility and broadening its investor

About Deutsche Bank Trust & Securities Services

Deutsche Bank’s Trust & Securities Services business, part of Global
Transaction Banking, is one of the leading providers of trustee, agent,
depositary, registrar, SPV management and related services for a wide range of
financial structures and transactions. It is a leading depositary for American
and Global Depositary Receipts, providing value-added services to companies
raising capital in international markets or listing on the New York, NASDAQ,
London, Luxembourg, Singapore or NASDAQ Dubai stock exchanges by means of
depositary receipts. It also offers both mutual and alternative fund
administration and provides securities custody, clearing and agency lending
services from a global network spanning more than 30 markets. Additional
details are available on or

This announcement appears as a matter of record only. This announcement has
been approved and/or communicated by Deutsche Bank AG New York.

The Depositary Receipts have been registered pursuant to the US Securities Act
of 1933 (the "Act"). The investment or investment service which is the subject
of this notice is not available to retail clients as defined by the UK
Financial Services Authority. This notice has been approved and/or
communicated by Deutsche Bank AG London. The services described in this notice
are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its
subsidiaries and/or affiliates in accordance with appropriate local
registration and regulation. Deutsche Bank is providing the attached notice
strictly for information purposes and makes no claims or statement, nor does
it warrant or in any way represent, as to the accuracy or completeness of the
details contained herein or therein. This announcement appears as a matter of
record only. Neither this announcement nor the information contained herein
constitutes an offer or solicitation by Deutsche Bank or any other issuer or
entity for the purchase or sale of any securities nor does it constitute a
solicitation to any person in any jurisdiction where solicitation would be
unlawful. No part of this notice may be copied or reproduced in any way
without the prior written consent of Deutsche Bank. Past results are not an
indication of future performance. Copyright© December 2012 Deutsche Bank AG.
All rights reserved.


Deutsche Bank AG
Press & Media Relations
Mayura Hooper, +1 212 250 5536
Press spacebar to pause and continue. Press esc to stop.